Anatara Lifesciences Ltd


Anatara Lifesciences ASX ANRAnatara Lifesciences (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for animal and human health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders. For more information, please visit



FINANCE VIDEO: Anatara Lifesciences Ltd (ASX:ANR) Interview with CEO Steve Lydeamore

🕔11/15/2019 7:46:07 AM 22

Anatara Lifesciences Ltd (ASX:ANR) CEO Steve Lydeamore is interviewed by ABN Newswire, and talks about the human trials as well as the product pipeline for next year.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Chairman's Address and AGM Presentation

🕔11/11/2019 11:29:07 AM 581

As Anatara moves forward, the Board is confident in the knowledge that a substantial market opportunity for Detach(R) remains, with more pressure than ever on producers to reduce their antibiotic use and find suitable alternatives which minimise illnesses, such as scour, on farms.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Investor Presentation

🕔10/23/2019 8:23:31 AM 808

Anatara Lifesciences (ASX:ANR) is pleased to release to investors a copy of the presentation that Chief Executive Officer, Mr Steven Lydeamore, will present today at the 10th Annual Australian Microcap Investment Conference, held in Melbourne, VIC.

Read Full Article

Anatara Lifesciences (ASX:ANR) "The Health Kick" podcast with Tim Boreham

🕔10/18/2019 9:52:35 AM 1019

Anatara Lifesciences CEO Steve Lydeamore sat down with Tim Boreham this week for Stockhead's new podcast series, "The Health Kick".

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Quarterly Financial Report

🕔10/17/2019 10:27:27 AM 990

Forecast expenditure for the December 2019 quarter is anticipated to increase as the Company advances the development of its Gastrointestinal Reprogramming (GaRP) dietary supplement. A refund from the Australian Taxation Office under the Federal Government's Research and Development (R&D) Tax Incentive scheme is anticipated to be received in December 2019.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Reports Statistically Significant Animal Studies

🕔10/14/2019 10:13:52 AM 1016

Anatara Lifesciences Ltd (ASX:ANR) is pleased to report statistically significant efficacy data from its in vivo mouse studies and further positive in vitro proof of concept data for its Gastrointestinal ReProgramming (GaRP) product.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Annual Report to Shareholders

🕔10/11/2019 10:08:13 AM 1023

Anatara Lifesciences Ltd's (ASX:ANR) lead human health product, GaRP, is being developed to specifically target two human gastrointestinal (GI) disorders, Inflammatory Bowel Disease (IBD) and Irritable Bowel Syndrome (IBS), where there is a significant unmet medical need.

Read Full Article

Tim Boreham interviews Anatara CEO Steven Lydeamore for Dr Boreham's Crucible

🕔9/2/2019 10:21:31 AM 1370

Anatara Lifesciences (ASX:ANR) CEO Steve Lydeamore recently spoke with experienced business writer, Tim Boreham, for his Dr Boreham's Crucible column which was published in Biotech Daily on Friday night and then reproduced in Stockhead across the weekend.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Message from the CEO

🕔8/30/2019 1:12:03 PM 1569

The 2018-2019 year has been a year of transition for Anatara Lifesciences (ASX:ANR), having commenced the year with a clear focus on successfully evolving into a human health company, through the pursuit of the burgeoning gastrointestinal health market.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) 2019 Financial Report

🕔8/27/2019 9:46:10 AM 1354

Anatara Lifesciences (ASX:ANR) today released its Appendix 4E and review of operations for the period ending 30th June 2019.

Read Full Article


  • This Page Viewed: (Last 7 Days: 393) (Last 30 Days: 1537) (Since Published: 42759) 

Company Data

  • 433 Logan Road, Stones Corner
    Brisbane, Queensland 4120
  • Principal Sector
  • Biotech 
  • Principal Industry
  • Biotechnology 
  • Homepage
  • E:

Company Reports